Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs

Abstract

This platform provides an innovative solution to inform or even replace phase 2a EBA trials, to bridge the gap between mouse efficacy studies and phase 2b and phase 3 trials, and to substantially accelerate drug development.